Aims: We aimed to incorporate a pharmacologically inactive midazolam microdose into early clinical studies for the assessment of CYP3A drug–drug interaction liability. Methods: Three early clinical studies were conducted with substances (Compounds A, B and C) which gave positive CYP3A perpetrator signals in vitro. A 75 μg dose of midazolam was administered alone (baseline CYP3A activity)...
Addiction BiologyDecember 1, 2003Nahal Ketabi‐Kiyanvash, Johanna Weiss, Walter Emil Haefeli et al.
Abstract: There are increasing numbers of deaths related to taking MDMA, MDE and PMA reported where the deceased typically took several different drugs with these compounds. Hence, mutual modulation of the pharmacokinetics in drug combinations with “ecstasy” might be a risk factor for “ecstasy”‐related morbidity. Regarding potential drug‐drug interactions, there are no data evaluating a...